Zomedica Corp. (ZOM)
|Net Income (ttm)||-18.50M|
|Trading Day||July 23|
|Day's Range||0.608 - 0.632|
|52-Week Range||0.063 - 2.910|
Zomedica came public too soon, but it does have enough cash to see a finish line. The question is, can ZOM stock investors afford to wait?
ZOM stock has come under price pressure recently, but the outlook is bright as Zomedica plots a road map to success. The post Ignore Zomedica's Recent Struggles.
Two of the assays used by Zomedica's Truforma platform aren't yet available. That continues to put downward pressure on ZOM stock.
It's not there yet, but if ZOM stock pulls back another 50% or so, the risk/return proposition will be more in your favor. The post Wait for Zomedica to Give Up More of its Meme Stock Gains appeared fir...
ZOM stock is rife with massive potential. But it's the same potential that has gone unfulfilled for the past few months.
These penny stocks are trading at cheap valuations, but they also have the potential to make major waves this year. The post 7 Penny Stocks You Can Pick Up for Less Than a Dollar appeared first on Inves...
ZOM stock is trading below $1 as investors are in a holding pattern as they wait for the company to report earnings in August. The post A Little Patience Could Go a Long Way For ZOM Stock appeared first...
Are these industry-leading penny stocks worth watching right now? The post 7 Industry Leading Penny Stocks To Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
Are these hot penny stocks on your watchlist this week? The post 9 Hot Penny Stocks to Watch For the Upcoming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
FOCUSED ON TRUFORMA ® INSTRUMENT PLACEMENTS AND BUILDING DIRECT SALES ORGANIZATION
Some stocks you can buy and forget. With Zomedica and ContextLogic, you'll want to keep a much closer eye on matters.
Making a penny stocks watchlist for July? Check these 8 out The post Penny Stocks To Buy in 2021?
InvestorPlace's Mark Hake estimates Zomedica is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy.
Zomedica is due to report results for the current quarter on Aug. 11. Until then, investors have nothing with which to weigh ZOM stock.
Diversify your portfolio with 7 high-return penny stocks that could be the next big thing based on facts instead of fantasy. The post 7 Penny Stocks That Could Be the Next Big Thing appeared first on In...
On paper, ZOM stock seems like a no-brainer due to enthusiasm for pet ownership but dig deeper and you'll find less promising data. The post Zomedica Stock Has More Headwinds Than the Rest of the Pet In...
Zomedica may have to contend with very difficult competition, and there are indications that Truforma is not very popular so far. ZOM stock looks very risky.
These penny stocks under $1 have the potential to trend higher. They are the stocks of businesses with decent fundamentals.
The hype surrounding ZOM stock has worn off, and it's now time for the company to prove its value through its sales numbers. The post Zomedica Pharmaceuticals Has to Prove Itself to Long-Term Investors ...
Zomedica is good value looks like it will go on the acquisition warpath. ZOM stock is worth between $1.11 and $1.61, or $1.36 on average, providing an average 20% ROI over 2 years.
ZOM stock has spiked sharply this year, but a recent price pullback could signal an ideal entry point for pet care market investors. The post Zomedica Is Surprisingly Cheap Even as Commercialization Com...
Penny stocks are not usually on lists of must-buy stocks, but that does not mean these companies cannot explode in the coming weeks. The post 7 Penny Stocks To Watch Before They Pop Due to Reddit Users ...
Which biotech penny stocks are on your watchlist as Covid comes to an end? The post Top Biotech Penny Stocks to Buy?
Reddit penny stocks are back in focus as AMC stock rises; which 3 are you watching? The post Reddit Penny Stocks to Buy?
You may like ZOM stock as a pet lover, but not for its fundamentals, nor its valuation until it starts having credible financial results. The post Zomedica's Risks Are Too Big to Ignore appeared first o...
Zomedica has promising growth potential, but its high share count makes ZOM stock a risky investment. Here's what investors should know.
Another pullback in ZOM stock will put this long-term speculative play's odds in your favor if its Truforma product catches on. The post Zomedica Stock Will Be Worth The Risk After Another Drop appeared...
The skeptics might misinterpret the company's first-quarter revenue data, but a deeper dive should uncover reasons to hold on to ZOM stock. The post Right-Priced Zomedica Could Be an Investor's Best Fri...
Reopening penny stocks are in focus; here's 3 to watch right now The post Hot Penny Stocks To Buy Right Now? 3 Reopening Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Zomedica's Truforma machine has entered the vet equipment market, which is consolidating rapidly. That means results on whether this can work should come quickly for ZOM stock investors.
ZOM stock trades below $1 as investors wait to see if recent changes to the company's business model along with potential acquisitions can be a catalyst for revenue. The post Is Zomedica Making a Change...
This isn't where you'd expect the brightest and most successful investors to put their money to work.
Zomedica is testing its support levels at current prices. What does the maker of diagnostic equipment need to do to get ZOM stock back to $1?
ZOM stock makes for a better trading vehicle than an investment in spite of their noble effort to heal. It needs to hold recent lows or else.
Or will speculation lead to major disappointment?
Zomedica has lost the fast money crowd, but what remains could be a stronger longer-term play in ZOM stock. The post Why Zomedica Doesn't Need Reddit appeared first on InvestorPlace.
A new executive will oversee the company's growth initiatives.
Former Elanco Animal Health, Johnson & Johnson, Intuitive Surgical, and Enteromedics Business Development Executive Joins Team to Support Growth Opportunities
The bull market has certainly made new investors look like geniuses, as usual. But now is the true test and ZOM stock isn't likely to pass.
The share price of the Ann Arbor, Michigan-based animal health company has now gone from a pullback and into a steep decline. Since March 15th, ZOM stock has fallen 68% and is now below the $1 threshold...
ZOM stock attracts plenty of attention for its underlying pet care business and its wild potential but this game may be over. The post Zomedica Is Now a Low-Probability Gamble appeared first on Investor...
ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats,...
Zomedica has potential in a niche business. But the price of ZOM stock does not yet reflect that.
If Truforma truly is a game-changer, there's hope the company could grab part of a potential $10.5 billion animal diagnostics market. The post Why Zomedica Stock Isn't Worth Buying Right Now appeared fi...
Stocks are always doing one of three things: Moving higher, moving lower or staying the same. When they're moving higher the bulls (buyers) control the market.
While ZOM stock has been highly volatile, the business is progressing. The Truforma platform has launched and we'll start seeing revenue figures soon.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences... [Read more...]
Drug Manufacturers-Specialty & Generic
|Stock Exchange |
|Ticker Symbol |
According to one analyst, the rating for Zomedica stock is "Buy" and the 12-month stock price forecast is 1.20.